ABBVIE INC

NYSE: ABBV (AbbVie Inc.)

Last update: 01 Jun, 12:52AM

161.24

4.93 (3.15%)

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - General (US) Bullish Mixed
Drug Manufacturers - General (Global) Bullish Mixed
Stock AbbVie Inc. Bullish Bullish

Stockmoo Score

1.6

Similar Stocks

Stock Market Cap DY P/E P/B
ABBV 285 B 2.84% 48.13 50.39
JNJ 396 B 2.96% 24.83 5.53
PFE 162 B 5.85% - 1.85
BMY 84 B 5.71% - 5.95
LLY 864 B 0.52% 117.65 60.60
MRK 320 B 2.40% 140.50 6.89

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
Sector Healthcare
Industry Drug Manufacturers - General
Investment Style Large Value
52 Weeks Range
130.96 (-18%) — 182.89 (13%)
Price Target Range
200.00 (24%) — 218.00 (35%)
High 218.00 (Morgan Stanley, 35.20%) Buy
Median 209.00 (29.62%)
Low 200.00 (Cantor Fitzgerald, 24.04%) Buy
200.00 (Barclays, 24.04%) Buy
Average 208.00 (29.00%)
Total 7 Buy
Avg. Price @ Call 185.81
Firm Date Target Price Call Price @ Call
Piper Sandler 23 Aug 2024 209.00 (29.62%) Buy 197.55
02 Jul 2024 190.00 (17.84%) Buy 165.96
Morgan Stanley 12 Aug 2024 218.00 (35.20%) Buy 190.18
11 Jul 2024 196.00 (21.56%) Buy 169.91
Barclays 26 Jul 2024 200.00 (24.04%) Buy 185.16
Cantor Fitzgerald 26 Jul 2024 200.00 (24.04%) Buy 185.16
09 Jul 2024 200.00 (24.04%) Buy 168.05
Truist Securities 26 Jul 2024 210.00 (30.24%) Buy 185.16
Wells Fargo 26 Jul 2024 205.00 (27.14%) Buy 185.16
BMO Capital 19 Jul 2024 214.00 (32.72%) Buy 172.32

No data within this time range.

  • 3M
Date Type Details
06 Sep 2024 Announcement AbbVie Declares Quarterly Dividend
27 Aug 2024 Announcement AbbVie Awards Scholarships to 45 U.S. Students Living With Chronic Immune-Mediated Diseases
27 Aug 2024 Announcement SkinMedica® Revolutionizes Skin Hydration with the Introduction of HA5® Hydra Collagen Replenish + Restore Hydrator
19 Aug 2024 Announcement European Commission Grants Second Indication Approval for TEPKINLY® (epcoritamab) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
15 Aug 2024 CNBC Biden administration releases prices of 10 drugs in Medicare negotiations, says U.S. will save $6 billion in first year
06 Aug 2024 CNBC Healthy Returns: What drugmakers are saying about final negotiated prices with Medicare
01 Aug 2024 Announcement AbbVie Completes Acquisition of Cerevel Therapeutics
30 Jul 2024 Announcement Allergan Aesthetics Celebrates the Second Annual JUVÉDERM® Day
26 Jul 2024 Announcement AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
25 Jul 2024 Announcement AbbVie Reports Second-Quarter 2024 Financial Results
12 Jul 2024 Announcement AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Giant Cell Arteritis
10 Jul 2024 Announcement AbbVie Announces Appointment of Roopal Thakkar, M.D. as Executive Vice President, Research & Development and Chief Scientific Officer
02 Jul 2024 Announcement AbbVie to Host Second-Quarter 2024 Earnings Conference Call
01 Jul 2024 Announcement Robert A. Michael Assumes Role as AbbVie Chief Executive Officer
28 Jun 2024 Announcement AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
27 Jun 2024 Announcement AbbVie Acquires Celsius Therapeutics
27 Jun 2024 Announcement Introducing Allē Payment Plans, Powered by Cherry
26 Jun 2024 Announcement U.S. Food and Drug Administration Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma
25 Jun 2024 Announcement AbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa)
21 Jun 2024 Announcement AbbVie Declares Quarterly Dividend
20 Jun 2024 Announcement AbbVie Appoints Roxanne S. Austin as Lead Independent Director of the Board of Directors
18 Jun 2024 Announcement U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease
14 Jun 2024 Announcement AbbVie Recommends Shareholders Reject Tutanota's "Mini-Tender" Offer
13 Jun 2024 Announcement AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel Disease
11 Jun 2024 Announcement BOTOX® Cosmetic (onabotulinumtoxinA) Reveals 2024 Women Entrepreneur Grant Recipients
Show more
TTM Dividend Yield 2.84%
5Y Average Dividend Yield 4.08%
Expected Next Dividend Payment Nov 2024
Ex Date Announcement Date Payment Date Details
12 Apr 2024 15 Feb 2024 15 May 2024 1.55 Cash
12 Jan 2024 27 Oct 2023 15 Feb 2024 1.55 Cash
12 Oct 2023 08 Sep 2023 15 Nov 2023 1.48 Cash
13 Jul 2023 22 Jun 2023 15 Aug 2023 1.48 Cash
13 Apr 2023 16 Feb 2023 15 May 2023 1.48 Cash
12 Jan 2023 28 Oct 2022 15 Feb 2023 1.48 Cash
13 Oct 2022 09 Sep 2022 15 Nov 2022 1.41 Cash
14 Jul 2022 23 Jun 2022 15 Aug 2022 1.41 Cash
13 Apr 2022 17 Feb 2022 16 May 2022 1.41 Cash
13 Jan 2022 29 Oct 2021 15 Feb 2022 1.41 Cash
14 Oct 2021 10 Sep 2021 15 Nov 2021 1.3 Cash
14 Jul 2021 17 Jun 2021 16 Aug 2021 1.3 Cash
14 Apr 2021 18 Feb 2021 14 May 2021 1.3 Cash
14 Jan 2021 30 Oct 2020 16 Feb 2021 1.3 Cash
14 Oct 2020 11 Sep 2020 16 Nov 2020 1.18 Cash
14 Jul 2020 17 Jun 2020 14 Aug 2020 1.18 Cash
14 Apr 2020 20 Feb 2020 15 May 2020 1.18 Cash
14 Jan 2020 01 Nov 2019 14 Feb 2020 1.18 Cash
11 Oct 2019 06 Sep 2019 15 Nov 2019 1.07 Cash
12 Jul 2019 21 Jun 2019 15 Aug 2019 1.07 Cash
12 Apr 2019 22 Feb 2019 15 May 2019 1.07 Cash
14 Jan 2019 02 Nov 2018 15 Feb 2019 1.07 Cash
12 Oct 2018 08 Sep 2018 15 Nov 2018 0.96 Cash
12 Jul 2018 15 Jun 2018 15 Aug 2018 0.96 Cash
12 Apr 2018 15 Feb 2018 15 May 2018 0.96 Cash
11 Jan 2018 27 Oct 2017 15 Feb 2018 0.71 Cash
12 Oct 2017 08 Sep 2017 15 Nov 2017 0.64 Cash
12 Jul 2017 22 Jun 2017 15 Aug 2017 0.64 Cash
11 Apr 2017 16 Feb 2017 15 May 2017 0.64 Cash
11 Jan 2017 28 Oct 2016 15 Feb 2017 0.64 Cash
12 Oct 2016 09 Sep 2016 15 Nov 2016 0.57 Cash
13 Jul 2016 16 Jun 2016 15 Aug 2016 0.57 Cash
13 Apr 2016 18 Feb 2016 16 May 2016 0.57 Cash
13 Jan 2016 30 Oct 2015 16 Feb 2016 0.57 Cash
13 Oct 2015 11 Sep 2015 16 Nov 2015 0.51 Cash
13 Jul 2015 18 Jun 2015 14 Aug 2015 0.51 Cash
13 Apr 2015 19 Feb 2015 15 May 2015 0.51 Cash
13 Jan 2015 20 Oct 2014 13 Feb 2015 0.49 Cash
10 Oct 2014 19 Sep 2014 17 Nov 2014 0.42 Cash
11 Jul 2014 19 Jun 2014 15 Aug 2014 0.42 Cash
11 Apr 2014 20 Feb 2014 15 May 2014 0.42 Cash
13 Jan 2014 12 Dec 2013 14 Feb 2014 0.4 Cash
10 Oct 2013 19 Sep 2013 15 Nov 2013 0.4 Cash
11 Jul 2013 20 Jun 2013 15 Aug 2013 0.4 Cash
11 Apr 2013 15 Feb 2013 15 May 2013 0.4 Cash
11 Jan 2013 04 Jan 2013 15 Feb 2013 0.4 Cash
Show more

Annual Dividend Yield

Year Annual Dividend ($) Frequency/Year Yield %
2024 3.10 2 1.92
2023 5.92 4 3.82
2022 5.64 4 3.49
2021 5.20 4 3.84
2020 4.72 4 4.41
2019 4.28 4 4.83
2018 3.59 4 3.89
2017 2.56 4 2.65
2016 2.28 4 3.64
2015 2.02 4 3.41
2014 1.66 4 2.54
2013 1.60 4 3.03
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2024 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria